{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:47:23Z","timestamp":1782157643170,"version":"3.54.5"},"reference-count":35,"publisher":"Informa UK Limited","issue":"9","funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2017,6,13]]},"DOI":"10.1080\/14656566.2017.1329820","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T13:48:13Z","timestamp":1494510493000},"page":"945-952","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":59,"title":["Darolutamide (ODM-201) for the treatment of prostate cancer"],"prefix":"10.1080","volume":"18","author":[{"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[{"name":"Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,24]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"CIT0002","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2012: prostate cancer, estimated incidence, mortality and prevalence worldwide in 2012. 2015. Available from: http:\/\/globocan.iarc.fr\/old\/FactSheets\/cancers\/prostate-new.asp"},{"key":"CIT0003","unstructured":"American Cancer Society. Cancer facts and figures 2016. Atlanta (GA): American Cancer Society; 2016. p. 500816."},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv222"},{"key":"CIT0005","unstructured":"National Comprehensive Cancer Network. NCCN: National Comprehensive Cancer Network clinical practice guidelines in oncology: prostate cancer. Version 1. 2017. Available from: www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.10.104"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.2526"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.14090"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1081566"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1038\/srep12007"},{"key":"CIT0014","volume":"34","author":"Fizazi K","year":"2016","journal-title":"J Clin Oncol"},{"key":"CIT0015","volume-title":"Presented at: European Cancer Congress","author":"Moilanen A","year":"2013"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70240-2"},{"key":"CIT0017","volume-title":"Presented at: American Association of Pharmaceutical Scientists","author":"Taavitsainen P","year":"2016"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.09.046"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.01.005"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Fizazi K, Massard C, Bono P, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in castration-resistant, CYP17 inhibitor-na\u00efve prostate cancer: results from extended follow-up of the ARADES trial. Eur Urol Focus. Forthcoming, 2017. Available from: https:\/\/doi.org\/10.1016\/j.euf.2017.01.010","DOI":"10.1016\/j.euf.2017.01.010"},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"Shore ND, Tammela TL, Massard C, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-na\u00efve and CYP17 inhibitor-na\u00efve patients: follow-up from the ARADES and ARAFOR trials. Eur Urol Focus. Forthcoming, 2017. Available from: https:\/\/doi.org\/10.1016\/j.euf.2017.01.015","DOI":"10.1016\/j.euf.2017.01.015"},{"issue":"4","key":"CIT0024","volume":"32","author":"Shore N","year":"2014","journal-title":"J Clin Oncol"},{"key":"CIT0025","volume-title":"Zytiga (abiraterone acetate) [prescribing information]","year":"2016"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"CIT0027","volume-title":"Xtandi (enzalutamide) [prescribing information].","year":"2016"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.08.005"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.256"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.04.023"},{"key":"CIT0033","volume-title":"Presented at: International Society for Pharmacoeconomics and Outcomes Research","author":"Li T","year":"2015"},{"key":"CIT0034","volume-title":"Presented at: annual meeting of European Society of Medical Oncology","author":"Xie W","year":"2016"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0543-9"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2017.1329820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T12:09:37Z","timestamp":1599307777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2017.1329820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,24]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,6,13]]}},"alternative-id":["10.1080\/14656566.2017.1329820"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2017.1329820","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}